Zobrazeno 1 - 10
of 189
pro vyhledávání: '"T, van der Straaten"'
Autor:
Jacqueline S. L. Kloth, Ron H.J. Mathijssen, Henk-Jan Guchelaar, Stefan Sleijfer, T. van der Straaten, Neeltje Steeghs, Jesse J. Swen, Michiel C. Verboom, Anna K.L. Reyners, Hans Gelderblom
Publikováno v:
Pharmacogenomics Journal
Pharmacogenomics journal, 18(1), 49-55. Nature Publishing Group
Pharmacogenomics Journal, 18(1), 49-55
Pharmacogenomics Journal, 18(1), 49-55. Nature Publishing Group
Pharmacogenomics journal, 18(1), 49-55. Nature Publishing Group
Pharmacogenomics Journal, 18(1), 49-55
Pharmacogenomics Journal, 18(1), 49-55. Nature Publishing Group
This study aimed to identify single-nucleotide polymorphisms (SNPs) that are associated with outcome to treatment with sunitinib in patients with advanced gastrointestinal stromal tumors (GIST). Forty-nine SNPS involved in the pharmacokinetic and pha
Autor:
Dirk Jan A.R. Moes, Akin Inderson, Henk-Jan Guchelaar, J. den Hartigh, T. van der Straaten, S. A. S van der Bent, Hein W. Verspaget, Jesse J. Swen, Erik Olofsen, B. van Hoek
Publikováno v:
European Journal of Clinical Pharmacology
European Journal of Clinical Pharmacology, 72(2), 163-74. Springer Verlag
European Journal of Clinical Pharmacology, 72(2), 163-174
Moes, D J A R, van der Bent, S A S, Swen, J J, van der Straaten, T, Inderson, A, Olofsen, E, Verspaget, H W, Guchelaar, H J, den Hartigh, J & van Hoek, B 2016, ' Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients ', European Journal of Clinical Pharmacology, vol. 72, no. 2, pp. 163-74 . https://doi.org/10.1007/s00228-015-1963-3
European Journal of Clinical Pharmacology, 72(2), 163-74. Springer Verlag
European Journal of Clinical Pharmacology, 72(2), 163-174
Moes, D J A R, van der Bent, S A S, Swen, J J, van der Straaten, T, Inderson, A, Olofsen, E, Verspaget, H W, Guchelaar, H J, den Hartigh, J & van Hoek, B 2016, ' Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients ', European Journal of Clinical Pharmacology, vol. 72, no. 2, pp. 163-74 . https://doi.org/10.1007/s00228-015-1963-3
Purpose The once daily formulation of tacrolimus is an important immunosuppressive drug. Interpatient variability in metabolism has been related to genetic variation in CYP3A4 and CYP3A5. However, in liver transplantation, both donor and recipient ge
Autor:
Frans L. Opdam, E. Maartense, J Hartigh den, T. van der Straaten, C.J.H. van de Velde, H-J Guchelaar, Patrick Neven, Carolien H. Smorenburg, Hein Putter, Anne-Sophie Dieudonné, J.W.R. Nortier, Vincent O. Dezentjé, Hans Gelderblom, R. Vree
Publikováno v:
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 153(3), 583-590
Breast Cancer Research and Treatment, 153(3), 583-590
Breast cancer patients with absent or reduced CYP2D6 activity and consequently low endoxifen levels may benefit less from tamoxifen treatment. CYP2D6 poor and intermediate metabolizers may need a personalized increased tamoxifen dose to achieve effec
Publikováno v:
Journal of Thrombosis and Haemostasis. 11:1850-1854
SummaryIntroduction Developmental hemostasis recognizes the physiologic differences between the hemostatic system of neonates and children and that of adults. As compared with the knowledge of hemostatic system physiology in adults, our understanding
Autor:
Henk-Jan Guchelaar, S. A. S van der Bent, T. van der Straaten, Jesse J. Swen, Akin Inderson, J. den Hartigh, B. van Hoek, Hein W. Verspaget, D J A R Moes, Erik Olofsen
Publikováno v:
European Journal of Clinical Pharmacology, 72(6), 775-6. Springer Verlag
European Journal of Clinical Pharmacology, 72(6), 775-776
European Journal of Clinical Pharmacology
Moes, D J A R, Swen, J J, van der Bent, S A S, van der Straaten, T, Inderson, A, Olofsen, E, Verspaget, H W, Guchelaar, H J, den Hartigh, J & van Hoek, B 2016, ' Response : Limited sampling strategies for once daily tacrolimus exposure monitoring ', European Journal of Clinical Pharmacology, vol. 72, no. 6, pp. 775-6 . https://doi.org/10.1007/s00228-016-2036-y
European Journal of Clinical Pharmacology, 72(6), 775-776
European Journal of Clinical Pharmacology
Moes, D J A R, Swen, J J, van der Bent, S A S, van der Straaten, T, Inderson, A, Olofsen, E, Verspaget, H W, Guchelaar, H J, den Hartigh, J & van Hoek, B 2016, ' Response : Limited sampling strategies for once daily tacrolimus exposure monitoring ', European Journal of Clinical Pharmacology, vol. 72, no. 6, pp. 775-6 . https://doi.org/10.1007/s00228-016-2036-y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39656d76dc2c44a543f1673df305709e
https://research.vumc.nl/en/publications/419ac2ee-8ad1-40c1-bed1-2ec470d6c361
https://research.vumc.nl/en/publications/419ac2ee-8ad1-40c1-bed1-2ec470d6c361
Autor:
T. van der Straaten, P.A. von dem Borne, Judith A.M. Wessels, H-J Guchelaar, M.H. ten Brink, J. den Hartigh, Juliette Zwaveling
Publikováno v:
Bone Marrow Transplantation, 47(2), 190-195
BU is used in conditioning regimens before hemopoietic SCT. High BU exposure is associated with toxicity, whereas low BU exposure leads to higher rates of therapy failure. The pharmacokinetics of BU show large interpatient variability, hypothesized t
Autor:
Hans de Fijter, Bart A. Ploeger, Meindert Danhof, T. van der Straaten, Henk-Jan Guchelaar, Hans van Pelt, Jan den Hartigh, Rogier R. Press
Publikováno v:
European Journal of Clinical Pharmacology, 66(6), 579-590
European Journal of Clinical Pharmacology
European Journal of Clinical Pharmacology
Purpose Optimal ciclosporin A (CsA) exposure in kidney transplant recipients is difficult to attain because of variability in CsA pharmacokinetics. A better understanding of the variability in CsA exposure could be a good means of individualizing the
Autor:
K. van der Weide, T. van der Straaten, Kirsten M. Pondman, Jan P.A.M. Bogers, Jan N. M. Commandeur, J. van der Weide, Harriet M. Loovers, Dan Cohen, Ellen Langemeijer
Publikováno v:
Pharmacogenomics Journal, 17(5), 471-478
Pharmacogenomics Journal. Nature Publishing Group
Van der Weide, K, Loovers, H, Pondman, K, Bogers, J, van der Straaten, T, Langemeijer, E V, Cohen, D, Commandeur, J N M & van der Weide, J 2016, ' Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population. ', Pharmacogenomics Journal . https://doi.org/10.1038/tpj.2016.32
Pharmacogenomics Journal. Nature Publishing Group
Van der Weide, K, Loovers, H, Pondman, K, Bogers, J, van der Straaten, T, Langemeijer, E V, Cohen, D, Commandeur, J N M & van der Weide, J 2016, ' Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population. ', Pharmacogenomics Journal . https://doi.org/10.1038/tpj.2016.32
Prescription of clozapine is complicated by the occurrence of clozapine-induced reduction of neutrophils. The aim of this study was to identify genetic risk factors in a population of 310 Dutch patients treated with clozapine, including 38 patients d
Genetics has significantly added to our understanding of variability in drug response, especially in cancer treatment. Pharmacogenetics, aimed at predicting a patient's chance for effective and safe drug treatment by interrogating germ line genetic v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ec8173d1fe1495a8bc9642692df2f72
https://hdl.handle.net/1887/104636
https://hdl.handle.net/1887/104636
Autor:
J A Romijn, A.G. Uitterlinden, A. Hofman, Nico Lakenberg, T. van der Straaten, Rob G H H Nelissen, Nienke R. Biermasz, Marian Beekman, Ingrid Meulenbelt, Margreet Kloppenburg, Herman M. Kroon, P.E. Slagboom, J. Bijsterbosch, J.B. van Meurs, Kim M J A Claessen, Alberto M. Pereira, B.J. Duijnisveld
Publikováno v:
Annals of the Rheumatic Diseases, 73(2), 433-436. BMJ Publishing Group
Annals of the rheumatic diseases, 73(2), 433-436. BMJ Publishing Group
Annals of the Rheumatic Diseases, 73(2), 433-436
Annals of the rheumatic diseases, 73(2), 433-436. BMJ Publishing Group
Annals of the Rheumatic Diseases, 73(2), 433-436
Background Several studies suggest a role of the growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis in the pathophysiology of primary osteoarthritis (OA). A common polymorphism of the GH receptor (exon 3 deletion, d3-GHR) is associated wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71a44794da8cfe75a8a763bc2174ed72
https://hdl.handle.net/1887/106101
https://hdl.handle.net/1887/106101